Blood Component & Testing - Part 2
Blood Components and Testing
Red Blood Cells (RBCs)
Overview of RBCs
Discussed as one of the main components from a whole blood unit.
Freezing RBCs
Stored at 1°C to 6°C for up to six days before being frozen.
Cryoprotectant used is glycerol, which is commonly employed for freezing.
Deglycerized Red Cells
Process involves thawing and washing cells to remove leukocytes, platelets, and plasma.
Two types of glycerol used: high glycerol and low glycerol.
High Glycerol: Most common, uses uncontrolled freezing.
Low Glycerol: Uses liquid nitrogen for controlled freezing.
Storage and Shelf Life
Frozen RBCs kept at -65°C and can be stored for ten years.
Usage in Rare Phenotypes
Frozen RBCs utilized for rare phenotypes, such as donors without the Solano antigen.
Used in certain disease states like paroxysmal nocturnal hemoglobinuria (PNH) and IgA deficiency.
Patients with IgA deficiency may use autologous donations, freezing their own blood for later use.
Military Use
Frozen RBCs used by military to maintain blood inventories.
Post-Thawing
After thawing and deglycerizing, RBCs must be used within 24 hours due to glycerol remnants.
Fresh Frozen Plasma (FFP)
Definition and Purpose
FFP is the fluid component of blood that contains all clotting factors.
Most common plasma component derived from whole blood.
Preparation
Blood must be collected without delay, ideally less than eight hours old.
Logistics may require timely courier transport to limit delays.
Indications for Use
Utilized for clotting deficiencies and trauma to maintain hemostasis.
Administered during surgeries and in cases of liver disease where clotting factors are produced.
Effective in treating disseminated intravascular coagulation (DIC).
Preparation Process
Blood is centrifuged; packed cells settle at the bottom.
Plasma is then expressed into a satellite bag to keep red cells separate.
Must be frozen at -18°C or lower after initial processing.
Thawing and Storage
Thawing methods: preferably in a water bath rather than an FDA-approved microwave.
Thawed FFP stored at 1°C to 6°C for 24 hours, used within that time frame due to manipulation.
Plasma Exchange
Plasma exchange involves replacing patient plasma with FFP to dilute certain conditions.
Other Plasma Products
Cryoprecipitate Reduced Plasma
Produced from thawed FFP; centrifuging separates cryoprecipitate.
Contains albumin, factors II, V, VII, IX, X, XI, and von Willebrand's factors.
Must be refrozen within 24 hours of preparation.
Single Donor Plasma
Prepared by freezing a unit within 8 to 24 hours of collection.
Can be stored for five days at 1°C to 6°C.
Commonly used for patients with active bleeding or multiple clotting factor deficiencies.
Soldier Plasma Storage
Similar storage conditions and shelf life to FFP, minus cryoprecipitate.
Platelet Concentrates
Production
Created by centrifuging platelet-rich plasma from whole blood through hard spins (3,600 to 5,000 RPM for 5-7 minutes).
Plasma is removed, retaining a small volume for platelet suspension.
pH and Concentration
Target pH must be greater than or equal to 6.2.
Minimum of 5.5 × 10^10 platelets must be present in the concentrate.
Historical context of pH measurement methods and their inadequacies discussed.
Storage and Shelf Life
Platelet concentrates stored at 20°C to 24°C under gentle agitation, only good for five days.
Pooled platelets have a shorter shelf life of four hours.
Donor Criteria
Must label platelets from donors who have taken aspirin, as it can affect platelet function.
Platelet Lesions
Concerns include bacterial contamination leading to increased risk factors due to temperature and handling.
Issues with ATP, ADP levels, and implications for platelet viability if pH falls below target.
Indications for Use of Platelets
General Usage
Used in actively bleeding patients with thrombocytopenia (commonly defined as a platelet count lower than 50,000/μl).
Cancer patients with induced thrombocytopenia typically see counts lower than 20,000/μl, necessitating transfusions.
Oncology practices recognize counts below 10,000/μl as critical.
Platelet Apheresis
Required for patients with previous HLA exposure to ensure compatibility.
Reduces exposure risks by limiting platelet donations to one donor rather than multiple.
Cryoprecipitate
Contents
Comprises von Willebrand factor, factor VIII, factor XIII, and fibrinogen.
Preparation
Created from frozen FFP; thawed at 1°C to 6°C, leading to the precipitation of cryoprecipitate.
Requires separation and refreezing.
Storage
Good at -18°C or lower for one year; thawed cryo valid for six hours.
Indications for Use
Supplementation for patients with deficiencies in factor XIII or fibrinogen.
Previously utilized as a fibrin sealant in various surgical procedures (e.g., cardiac, dental).
Current advancements include pharmaceutical alternatives for treatment of hemophilia A and von Willebrand disease.